Kopran Limited, an integrated pharmaceutical company, manufactures and sells active pharmaceutical ingredients and finished dosage forms in India and internationally. More Details
Flawless balance sheet with outstanding track record.
Share Price & News
How has Kopran's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: KOPRAN is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: KOPRAN's weekly volatility (7%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: KOPRAN exceeded the Indian Pharmaceuticals industry which returned 43.4% over the past year.
Return vs Market: KOPRAN exceeded the Indian Market which returned 60.8% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Kopran's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StThese 4 Measures Indicate That Kopran (NSE:KOPRAN) Is Using Debt Safely
2 months ago | Simply Wall StIf You Had Bought Kopran (NSE:KOPRAN) Stock A Year Ago, You Could Pocket A 327% Gain Today
2 months ago | Simply Wall StKopran Limited's (NSE:KOPRAN) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
Is Kopran undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: KOPRAN (₹137.45) is trading below our estimate of fair value (₹162.55)
Significantly Below Fair Value: KOPRAN is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: KOPRAN is good value based on its PE Ratio (10.8x) compared to the IN Pharmaceuticals industry average (20.6x).
PE vs Market: KOPRAN is good value based on its PE Ratio (10.8x) compared to the Indian market (18.2x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate KOPRAN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: KOPRAN is overvalued based on its PB Ratio (2.5x) compared to the IN Pharmaceuticals industry average (2.3x).
How is Kopran forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Kopran has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Kopran performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: KOPRAN has high quality earnings.
Growing Profit Margin: KOPRAN's current net profit margins (11.7%) are higher than last year (6.4%).
Past Earnings Growth Analysis
Earnings Trend: KOPRAN has become profitable over the past 5 years, growing earnings by 20.8% per year.
Accelerating Growth: KOPRAN's earnings growth over the past year (115.3%) exceeds its 5-year average (20.8% per year).
Earnings vs Industry: KOPRAN earnings growth over the past year (115.3%) exceeded the Pharmaceuticals industry 39.9%.
Return on Equity
High ROE: KOPRAN's Return on Equity (23.3%) is considered high.
How is Kopran's financial position?
Financial Position Analysis
Short Term Liabilities: KOPRAN's short term assets (₹2.5B) exceed its short term liabilities (₹1.4B).
Long Term Liabilities: KOPRAN's short term assets (₹2.5B) exceed its long term liabilities (₹327.9M).
Debt to Equity History and Analysis
Debt Level: KOPRAN's debt to equity ratio (28.5%) is considered satisfactory.
Reducing Debt: KOPRAN's debt to equity ratio has reduced from 68.3% to 28.5% over the past 5 years.
Debt Coverage: KOPRAN's debt is well covered by operating cash flow (77.5%).
Interest Coverage: KOPRAN's interest payments on its debt are well covered by EBIT (14.4x coverage).
What is Kopran current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: KOPRAN's dividend (2.33%) is higher than the bottom 25% of dividend payers in the Indian market (0.44%).
High Dividend: KOPRAN's dividend (2.33%) is in the top 25% of dividend payers in the Indian market (1.93%)
Stability and Growth of Payments
Stable Dividend: Too early to tell whether KOPRAN's dividend payments have been stable as they only just started paying a dividend.
Growing Dividend: Too early to tell if KOPRAN's dividend payments are increasing as they only just started paying a dividend.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Kopran has no CEO, or we have no data on them.
Experienced Management: KOPRAN's management team is seasoned and experienced (6.8 years average tenure).
Experienced Board: KOPRAN's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Kopran Limited's company bio, employee growth, exchange listings and data sources
- Name: Kopran Limited
- Ticker: KOPRAN
- Exchange: NSEI
- Founded: 1958
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹5.895b
- Shares outstanding: 43.25m
- Website: https://www.kopran.com
Number of Employees
- Kopran Limited
- Parijat House
- 1076, Dr. E Moses Road
Kopran Limited, an integrated pharmaceutical company, manufactures and sells active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers finished dosage for...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/21 12:16|
|End of Day Share Price||2021/04/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.